Editor's Highlights-March 2025.

Abstract

Managing chronic inflammatory skin diseases such as hidradenitis suppurativa (HS) and psoriasis extends beyond clinical measures; it should also consider patient-reported outcomes, treatment burden, and overall satisfaction. Successful therapy in both conditions is influenced by factors such as residual disease activity, the psychological profiles of patients, and the availability of new treatment options. The coexistence of psoriasis and atopic dermatitis can pose significant diagnostic and therapeutic challenges. In such rare cases, Janus kinase inhibitors may be considered a treatment option instead of biologics.